blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3071215

EP3071215 - COMPOSITIONS AND METHODS FOR TREATING PULMONARY HYPERTENSION [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  13.11.2020
Database last updated on 28.05.2024
FormerThe patent has been granted
Status updated on  06.12.2019
FormerGrant of patent is intended
Status updated on  08.07.2019
FormerExamination is in progress
Status updated on  04.05.2018
Most recent event   Tooltip08.07.2022Lapse of the patent in a contracting state
New state(s): AL, MK		published on 10.08.2022  [2022/32]
Applicant(s)For all designated states
The Brigham and Women's Hospital, Inc.
75 Francis Street
Boston, MA 02115 / US
For all designated states
Acceleron Pharma Inc.
128 Sidney Street
Cambridge, MA 02139 / US
[2016/39]
Inventor(s)01 / YU, Paul
1105
234 Causeway Street
Boston, Massachusetts 02114 / US
02 / GRINBERG, Asya
37 Follen Road
Lexington, Massachusetts 02421 / US
03 / SAKO, Dianne S.
14 Mystic Street
Medford, Massachusetts 02155 / US
04 / CASTONGUAY, Roselyne
19 James Street
Watertown, Massachusetts 02472 / US
05 / STEEVES, Rita
68 Collincote Street
Stoneham, Massachusetts 02180 / US
06 / KUMAR, Ravindra
421 Arlington Street
Acton, Massachusetts 01720 / US
 [2016/43]
Former [2016/39]01 / YU, Paul
1105
234 Causeway Street
Boston, Massachusetts 02114 / US
02 / GRINBERG, Asya
12468 Main Campus Drive
Lexington, Massachusetts 02421 / US
03 / SAKO, Dianne S.
14 Mystic Street
Medford, Massachusetts 02155 / US
04 / CASTONGUAY, Roselyne
32 Grace Street
Malden, Massachusetts 02148 / US
05 / STEEVES, Rita
68 Collincote Street
Stoneham, Massachusetts 02180 / US
06 / KUMAR, Ravindra
421 Arlington Street
Acton, Massachusetts 01720 / US
Representative(s)Kehoe, Laura Ellen, et al
Keltie LLP
No.1 London Bridge
London SE1 9BA / GB
[2016/39]
Application number, filing date14864524.521.11.2014
[2016/39]
WO2014US66776
Priority number, dateUS201361907260P21.11.2013         Original published format: US 201361907260 P
[2016/39]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2015077540
Date:28.05.2015
Language:EN
[2015/21]
Type: A2 Application without search report 
No.:EP3071215
Date:28.09.2016
Language:EN
The application published by WIPO in one of the EPO official languages on 28.05.2015 takes the place of the publication of the European patent application.
[2016/39]
Type: B1 Patent specification 
No.:EP3071215
Date:08.01.2020
Language:EN
[2020/02]
Search report(s)International search report - published on:US19.11.2015
(Supplementary) European search report - dispatched on:EP25.07.2017
ClassificationIPC:A61K38/17, A61K39/00, C12N15/62, C07K14/71, A61P11/00, A61P9/12
[2017/20]
CPC:
A61K38/179 (EP,US); A61K47/6811 (US); A61P11/00 (EP);
A61P9/00 (EP); A61P9/12 (EP,US); C07K14/71 (EP,US);
C07K19/00 (US); C07K2319/30 (EP,US); C07K2319/32 (US) (-)
Former IPC [2016/39]A61K38/00, A61K39/00
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2016/39]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:ZUSAMMENSETZUNGEN UND VERFAHREN ZUR BEHANDLUNG PULMONALER HYPERTONIE[2016/39]
English:COMPOSITIONS AND METHODS FOR TREATING PULMONARY HYPERTENSION[2016/39]
French:COMPOSITIONS ET PROCÉDÉS DE TRAITEMENT DE L'HYPERTENSION PULMONAIRE[2016/39]
Entry into regional phase20.06.2016National basic fee paid 
20.06.2016Search fee paid 
20.06.2016Designation fee(s) paid 
20.06.2016Examination fee paid 
Examination procedure20.06.2016Examination requested  [2016/39]
19.02.2018Amendment by applicant (claims and/or description)
08.05.2018Despatch of a communication from the examining division (Time limit: M04)
03.09.2018Reply to a communication from the examining division
19.11.2018Despatch of a communication from the examining division (Time limit: M06)
23.04.2019Reply to a communication from the examining division
09.07.2019Communication of intention to grant the patent
04.11.2019Fee for grant paid
04.11.2019Fee for publishing/printing paid
04.11.2019Receipt of the translation of the claim(s)
Divisional application(s)EP20150385.1  / EP3685848
EP21190858.7  / EP4005585
EP24166565.2
Opposition(s)09.10.2020No opposition filed within time limit [2020/51]
Fees paidRenewal fee
28.11.2016Renewal fee patent year 03
27.11.2017Renewal fee patent year 04
27.11.2018Renewal fee patent year 05
27.11.2019Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU21.11.2014
AL08.01.2020
AT08.01.2020
CY08.01.2020
CZ08.01.2020
EE08.01.2020
FI08.01.2020
HR08.01.2020
LT08.01.2020
LV08.01.2020
MC08.01.2020
MK08.01.2020
MT08.01.2020
PL08.01.2020
RO08.01.2020
RS08.01.2020
SE08.01.2020
SI08.01.2020
SK08.01.2020
SM08.01.2020
TR08.01.2020
BG08.04.2020
NO08.04.2020
GR09.04.2020
IS08.05.2020
PT31.05.2020
[2022/31]
Former [2022/27]HU21.11.2014
AT08.01.2020
CY08.01.2020
CZ08.01.2020
EE08.01.2020
FI08.01.2020
HR08.01.2020
LT08.01.2020
LV08.01.2020
MC08.01.2020
MT08.01.2020
PL08.01.2020
RO08.01.2020
RS08.01.2020
SE08.01.2020
SI08.01.2020
SK08.01.2020
SM08.01.2020
TR08.01.2020
BG08.04.2020
NO08.04.2020
GR09.04.2020
IS08.05.2020
PT31.05.2020
Former [2021/31]AT08.01.2020
CZ08.01.2020
EE08.01.2020
FI08.01.2020
HR08.01.2020
LT08.01.2020
LV08.01.2020
MC08.01.2020
PL08.01.2020
RO08.01.2020
RS08.01.2020
SE08.01.2020
SI08.01.2020
SK08.01.2020
SM08.01.2020
BG08.04.2020
NO08.04.2020
GR09.04.2020
IS08.05.2020
PT31.05.2020
Former [2021/11]AT08.01.2020
CZ08.01.2020
EE08.01.2020
FI08.01.2020
HR08.01.2020
LT08.01.2020
LV08.01.2020
PL08.01.2020
RO08.01.2020
RS08.01.2020
SE08.01.2020
SI08.01.2020
SK08.01.2020
SM08.01.2020
BG08.04.2020
NO08.04.2020
GR09.04.2020
IS08.05.2020
PT31.05.2020
Former [2020/50]CZ08.01.2020
EE08.01.2020
FI08.01.2020
HR08.01.2020
LT08.01.2020
LV08.01.2020
RO08.01.2020
RS08.01.2020
SE08.01.2020
SK08.01.2020
SM08.01.2020
BG08.04.2020
NO08.04.2020
GR09.04.2020
IS08.05.2020
PT31.05.2020
Former [2020/49]CZ08.01.2020
FI08.01.2020
HR08.01.2020
LT08.01.2020
LV08.01.2020
RO08.01.2020
RS08.01.2020
SE08.01.2020
SK08.01.2020
SM08.01.2020
BG08.04.2020
NO08.04.2020
GR09.04.2020
IS08.05.2020
PT31.05.2020
Former [2020/48]FI08.01.2020
HR08.01.2020
LT08.01.2020
LV08.01.2020
RO08.01.2020
RS08.01.2020
SE08.01.2020
SM08.01.2020
BG08.04.2020
NO08.04.2020
GR09.04.2020
IS08.05.2020
PT31.05.2020
Former [2020/40]FI08.01.2020
HR08.01.2020
LT08.01.2020
LV08.01.2020
RS08.01.2020
SE08.01.2020
BG08.04.2020
NO08.04.2020
GR09.04.2020
IS08.05.2020
PT31.05.2020
Former [2020/39]FI08.01.2020
HR08.01.2020
LT08.01.2020
LV08.01.2020
RS08.01.2020
SE08.01.2020
BG08.04.2020
NO08.04.2020
GR09.04.2020
PT31.05.2020
Former [2020/38]FI08.01.2020
HR08.01.2020
LT08.01.2020
LV08.01.2020
RS08.01.2020
SE08.01.2020
NO08.04.2020
GR09.04.2020
PT31.05.2020
Former [2020/37]FI08.01.2020
HR08.01.2020
LT08.01.2020
LV08.01.2020
RS08.01.2020
SE08.01.2020
NO08.04.2020
PT31.05.2020
Former [2020/36]FI08.01.2020
LT08.01.2020
RS08.01.2020
NO08.04.2020
PT31.05.2020
Former [2020/35]FI08.01.2020
LT08.01.2020
NO08.04.2020
Documents cited:Search[Y]WO9848024  (BIOGEN INC [US], et al) [Y] 1,9-15 * the whole document * * claims 1-21 *;
 [Y]WO2012093125  (GLAXO GROUP LTD [GB], et al) [Y] 1,9-15 * the whole document ** page 30, line 23 - page 31, line 8 *;
 [E]WO2015027082  (ACCELERON PHARMA INC [US]) [E] 1,9-15 * the whole document *;
 [E]WO2016019368  (BRIGHAM & WOMENS HOSPITAL [US]) [E] 1,9-15 * the whole document * * example 2 *;
 [T]  - YUNG LAI-MING ET AL, "A Selective Transforming Growth Factor-beta Ligand Trap Attenuates Pulmonary Hypertension", AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, (20161101), vol. 194, no. 9, pages 1140 - 1151, XP009193771 [T] 1,9-15

DOI:   http://dx.doi.org/10.1164/rccm.201510-1955OC
 [XP]  - Anonymous, "Abstract 17285: A Selective Transforming Growth Factor-[beta] and Growth Differentiation Factor-15 Ligand Trap Attenuates Pulmonary Hypertension | Circulation", (20141107), URL: http://circ.ahajournals.org/content/130/Suppl_2/A17285, (20170320), XP055356458 [XP] 1,9-15 * the whole document *
 [XY]  - Megalou, "Introduction", (20100101), URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2971541/pdf/ijcem0003-0332.pdf, (20170321), XP055356798 [X] 1,9,12-15 * the whole document * [Y] 1,9-15
 [Y]  - RABBANI Z N ET AL, "Soluble TGFbeta type II receptor gene therapy ameliorates acute radiation-induced pulmonary injury in rats", INTERNATIONAL JOURNAL OF RADIATION: ONCOLOGY BIOLOGY PHYSICS, PERGAMON PRESS, USA, (20030101), vol. 57, no. 2, doi:10.1016/S0360-3016(03)00639-4, ISSN 0360-3016, pages 563 - 572, XP002298762 [Y] 1,9-15 * the whole document *

DOI:   http://dx.doi.org/10.1016/S0360-3016(03)00639-4
International search[X]WO2012145539  (ACCELERON PHARMA INC [US], et al) [X] 23 * ; page 14, lines 9-11; page 38, lines 12-13; page 52, lines 30-31; page 53, lines 10-16; page 74, line 4 *;
 [X]WO2013019805  (TUFTS MEDICAL CT INC [US], et al) [X] 1-3, 22, 25, 27, 30, 32, 34 * ; page 1, lines 30-34; page 9, lines 18-20; page 12, lines 25-26; page 18, lines 18-35 *;
 [Y]  - MEADOWS, C et al., "Increased Expression of Growth Differentiation Factor-15 in Systemic Sclerosis-Assiciated Pulmonary Arterial Hypertension.", Chest, (20100909), vol. 139, pages 994 - 1002, XP055237245 [Y] 22, 30 * : abstract: page 995, left column, second paragraph. doi: 10.1378/chest.10-03C *
 [Y]  - GONZALEZ-NUNEZ, M et al., "The ALK-1/Smad1 Pathway In Cardiovascular Physiopathology: New Target for Therapy?", Biochim Biophys Acta, (20130522), vol. 1832, no. 10, pages 1492 - 1510, XP055237247 [Y] 25, 32, 34 * ; page 1495; figure 1; page 1499, right column, fifth paragraph; page 1503, right column, fifth paragraph; page 1504, left column, third paragraph. DOI: 10,1016/j.bbadis.2013.05.016. *

DOI:   http://dx.doi.org/10.1016/j.bbadis.2013.05.016
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.